U.S. Paper and Forestry Products Stock News

McCormick stock has had a difficult few years with the share price down 33.7% over three years, yet the broader valuation checks now suggest the stock does not look obviously expensive at current levels. McCormick shares have declined 33.7% over the past three years, which raises the question of whether expectations for the business were set too high or if the current price is starting to factor in more modest assumptions. Future pricing power and margin resilience in McCormick's core spices...

Doximity entered this earnings week as a quietly discounted healthcare platform with a P/E below many digital health peers. The stock is no longer quiet. Shares surged about 33% in the first full session after the Q1 2027 report as investors rushed to reprice a business that is pouring money into clinical artificial intelligence while still generating strong profits. The headline is simple: Doximity delivered roughly $157 million of revenue and a 48% adjusted earnings before interest, taxes,...

In late July 2026, Silicon Motion Technology reported past second‑quarter sales of US$451.00 million and net income of US$136.11 million, and issued third‑quarter 2026 guidance for revenue of US$519.00 million to US$541.00 million with operating margin of 24.4% to 25.7%. Within days of these results, the company also introduced its MonTitan SSD Reference Design Kit with PerformaShape technology and showcased AI‑focused storage platforms for data centers, edge AI, and automotive “Physical...

SK hynix stock has fallen 17.9% year to date, which puts the current share price under pressure just as investors are reassessing what they are willing to pay for its memory and AI exposure. The 17.9% year to date decline raises the question of whether recent weakness has moved SK hynix closer to a valuation floor or if it simply reflects a reset in expectations. The approved US$38b build out of two new memory chip plants can support long term revenue potential tied to AI demand. However,...

Ardelyx stock just dropped 17.9% to about US$4, extending a three month slide that has taken roughly 41% off the share price. The hit looks harsh when set against what the company just posted. Q2 product revenue reached US$118 million, led by irritable bowel syndrome with constipation drug IBSRELA at US$86.2 million. The company still reported a loss of US$16.7 million, although that was smaller than in Q1. For a biotech like Ardelyx, the real story now sits in the multi year revenue targets,...

Macy's stock has delivered a very strong 1 year return, yet the valuation work suggests the shares may still be trading at a discount to what the underlying cash flows imply. Over the past year, Macy's has returned 118.2%, which puts more focus on whether recent buyers are overpaying or still getting in below intrinsic value. The key support for the current price is the market's view on Macy's ability to keep converting its retail footprint into steady cash flows. Any sustained pressure on...

In early August 2026, Ocular Therapeutix reported second-quarter 2026 results showing revenue of US$13.48 million, essentially flat year on year, while net loss widened to US$78.76 million alongside slightly improved loss per share metrics. On the same day, the company also filed an US$81.7 million shelf registration for up to 10,000,000 shares, highlighting an intention to maintain funding flexibility even after previously raising substantial cash to extend its runway. Against this backdrop...

Medtronic stock reaction to new CE Mark indication Medtronic (MDT) stock is in focus after the company received an expanded CE Mark indication for its Affera Mapping and Ablation System with Sphere-9 Catheter to treat ventricular arrhythmias. The device is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter with CE Mark for ventricular ablation. It also holds U.S. FDA Breakthrough Device Designation, with a pivotal trial now enrolling patients. See our latest...

Venture Global has had a strong run so far this year, and current valuation checks suggest the stock now trades closer to fair than obviously cheap levels. The stock is up 88.4% year to date, which puts more pressure on current expectations to justify the move. The recent Baker Hughes liquefaction technology order can support long term project visibility, while execution risk on large scale LNG developments may still weigh on how investors price the stock. Venture Global scores highly on...

In late July 2026, TriNet Group, Inc. reported second-quarter revenue of US$1,178 million versus US$1,238 million a year earlier, while net income rose to US$53 million from US$37 million and diluted earnings per share from continuing operations increased to US$1.15 from US$0.77. Despite lower revenue for both the quarter and first half, TriNet converted more of its top line into profit and lifted full-year 2026 revenue guidance to US$4.75–US$4.9 billion and diluted net income per share...

Kohl's stock has delivered a 79.0% return over the past year, yet valuation checks still indicate the shares screen as undervalued on several measures. With that backdrop and a recent change in board leadership, investors are weighing whether the current price still reflects a discount to the fundamentals. The 79.0% 1 year return points to a strong rebound in sentiment, which can raise the bar for what counts as good value from here. The appointment of Wendy Arlin as board chair and Niren...

Global-E Online Ltd. recently entered earnings season with analysts having expected quarterly earnings of US$0.22 per share for the June 2026 quarter, alongside forecast revenue of US$282.32 million and strong growth in core operational metrics such as fulfillment services revenue and gross merchandise value. This cluster of upbeat expectations highlights how Global-E’s cross-border e-commerce model and expanding service mix are increasingly central to analyst views on its growth...

Corvus Pharmaceuticals (CRVS) reported second quarter 2026 results today, with a wider net loss and higher loss per share from continuing operations, giving investors fresh information to reassess the stock. See our latest analysis for Corvus Pharmaceuticals. Corvus Pharmaceuticals has seen strong longer term momentum, with a year to date share price return of 90.16% and a very large 1 year total shareholder return of 222.97%. This comes even though the 30 day share price return is down...

In the past quarter ended June 30, 2026, American Financial Group, Inc. reported second-quarter revenue of US$2,030 million and net income of US$248 million, with diluted earnings per share from continuing operations of US$2.99, alongside a six‑month revenue of US$3,884 million and net income of US$439 million. Over the same period, the company also continued its long-running capital return program, repurchasing 200,231 shares for US$26 million and bringing total buybacks under its 2010...

International Business Machines (NYSE: IBM) reports multiple quantum advantage breakthroughs with research partners, including trusted computations that outperform leading classical methods on complex simulations. IBM unveils open benchmarking frameworks that allow independent verification of its quantum results, addressing long-standing questions on trust and error mitigation. US lawmakers place IBM at the center of a legislative push to expand federal quantum funding and policy,...

In the past quarter, Vir Biotechnology, Inc. reported Q2 2026 revenue of US$238.95 million, up sharply from US$1.21 million a year earlier, with net income of US$80.08 million replacing a prior net loss of US$110.96 million and earnings per share turning positive. An interesting twist is that despite this major swing toward profitability and revenue growth, the company still fell short of analyst expectations on both earnings and sales. Against this backdrop of improved profitability but an...

CF Industries Holdings just delivered one of the punchiest profit prints in the sector, yet the stock slipped about 2% on the day after earnings to around US$114. The market marked the price down. The earnings told a different story. Net income for the quarter landed at US$727 million with basic earnings per share of US$4.73, powered by what management frames as a new, higher mid cycle cash generation profile. Coming into the release, CF Industries Holdings had been treading water over the...

Aveanna Healthcare Holdings (AVAH) drew fresh attention after recent trading left the stock at a last close of $9.49, with investors weighing its home care focused business against mixed annual revenue and net income trends. See our latest analysis for Aveanna Healthcare Holdings. Recent trading reflects this tension, with a 1 day share price return of 1.93% and a 90 day share price return of 40.80%, alongside a 1 year total shareholder return of 54.56% and a very large 3 year total...

AbbVie stock has delivered a strong 153.8% return over the past 5 years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value suggesting meaningful upside while market multiples point to a richer price tag. For investors, the question is how to weigh that gap against the steady share price progress and recent product news around Rinvoq, Ubrelvy and the Allergan Aesthetics portfolio. AbbVie has returned 153.8% over 5 years, which puts recent short term share...

Patterson-UTI Energy, Inc. recently filed a US$296.803 million shelf registration for 28,900,000 common shares tied to an ESOP-related offering, and reported second-quarter 2026 sales of US$1,227.97 million with a net loss of US$19.6 million, narrower than a year earlier. The combination of improving analyst sentiment, upgraded full-year earnings estimates, and a smaller quarterly loss suggests investors are focusing on operational progress rather than headline losses alone. We’ll now...

Hyatt Hotels Corporation recently reported past second-quarter 2026 results, with revenue of US$1.83 billion, net income of US$110 million and diluted earnings per share of US$1.14, alongside affirming a US$0.15 quarterly dividend and updating full-year earnings guidance. The shift from a small net loss a year earlier to meaningful profitability, combined with ongoing share repurchases, highlights Hyatt’s focus on shareholder returns and operational efficiency. We’ll now examine how Hyatt’s...

Recent commentary on Bill Ackman’s Pershing Square (PS) portfolio, which concentrates seven stocks in about 98% of assets and includes Microsoft, Amazon, Uber and Meta Platforms, has drawn fresh attention to Pershing Square’s own listed shares. See our latest analysis for Pershing Square. Pershing Square’s share price return over the year has been strong, with a year to date share price return of 56.53% and a recent 7 day share price return of 13.82%. The 90 day share price return is down...

Procter & Gamble stock sits in an interesting spot right now. The Discounted Cash Flow (DCF) intrinsic value estimate points to a sizeable valuation gap, while the broader checks still flag only a mixed picture and the share price has delivered relatively modest gains over five years. Over the past 5 years, Procter & Gamble has returned 15.4%, which is a steady result rather than a runaway winner for long term holders. The planned US$3.8b acquisition of supplement brand Thorne may support...

KRR stock has fallen 27.5% over the past year but is still up 69.6% over three years, while valuation checks send mixed signals as the intrinsic value estimate suggests upside and earnings based multiples lean the other way. That split, set against a busy deal pipeline in infrastructure, energy and healthcare, is what current holders and potential buyers are trying to make sense of. KKR’s 69.6% gain over three years highlights how much of the long term value case has already been reflected...